Tuesday, December 02, 2008
 
 
  Home arrow Birth Control arrow Legal, Federal Action arrow FDA Refrains From Releasing the "Morning After Pill" Over The Counter (5/04)
Main Menu
Home
About Us
Current Headlines
Abortion
Abstinence
Birth Control
End of Life / Euthanasia
Medical Research
Medical Students
Population
Position Statements
Pregnancy/Development
STDs
Stem Cells & Cloning
Contact Us
Web Links
Site Index
Resources
Related Items
Translator
Quotes to Note
“A young woman with an unintended pregnancy clearly sacrifices the protective effect of a term delivery should she decide to abort and delay childbearing ... Thus, we conclude that informed consent before induced abortion should include information about the subsequent risk of preterm delivery and depression.”    --Thorpe et al., Obstetrical & Gynecological Survey, 1/2003

 

 
FDA Refrains From Releasing the "Morning After Pill" Over The Counter (5/04) PDF Print E-mail

The Food and Drug Administration (FDA) decided 6May04 that it will not allow over-the-counter sales of Plan B, the "morning after pill" (MAP; often referred to as "emergency contraception" or EC).  The drug is dangerous for women and can result in an abortion if the female egg ovulated prior to receiving MAP. The long-term effects of such high doses of estrogen have not been sufficiently studied. (The devastating effects of DES took many years to determine.)

For more articles regarding MAP/EC, click here.

The FDA made its decision based on concerns about the effects of the drug on teenagers. It would have been very likely that teens would have been exposed to greater sexual predation. MAP/EC only affects pregnancy; it does not block STD infection.

However, it left the door open to allowing the drugs to be sold to adults. The agency also said it would reconsider its decision if Barr Laboratories, maker of the Plan B morning after drug, would provide more details on teen's use of the drugs. Barr Labs said it was disappointed by the FDA's decision. Barr chief executive Bruce Downey said his company would seek nonprescription sales approval again, but this time for people 16 years or older. "The FDA has also provided us with pathways to a future approval, and we are committed to following the pathways until we get this product on the market over-the-counter," Downey said. Downey said he expected to be able to accomplish that in a matter of months. http://www.lifenews.com/nat498.html
 
< Prev   Next >


Go to top of page  Home | About Us | Current Headlines | Abortion | Abstinence | Birth Control | End of Life / Euthanasia | Medical Research | Medical Students | Population | Position Statements | Pregnancy/Development | STDs | Stem Cells & Cloning | Contact Us | Web Links | Site Index | Resources |
 
PhysiciansForLife.org Copyright (C) 2004-2008 All Rights Reserved